Rising Clinical Trial Complexity Continues to Vex Drug Developers, According to Tufts Center for the Study of Drug Development
May 05, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 5, 2010) - Growing clinical trial complexity continues to challenge the ability of pharmaceutical and biotechnology companies to contain the ever-rising cost of...
New Approaches to R&D May Prove Best Path for Drug Developers, According to Tufts Center for the Study of Drug Development
April 06, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 6, 2010) - Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the...
Regulatory Affairs Workload at Drug Development Firms Has Increased Dramatically, According to Tufts Center for the Study of Drug Development
March 11, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 11, 2010) - A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for...
Tufts Center for the Study of Drug Development Launches New Website to Support Research on Critical Drug Development Issues
January 28, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2010) - The Tufts Center for the Study of Drug
Development, the world's leading, independent authority on the nature and
pace of pharmaceutical and biotech drug...
Capacity Planning Is Becoming a Critical Success Factor for Drug Developers, According to Tufts Center for the Study of Drug Development
January 26, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 26, 2010) - Growing pressure within the research-based drug
industry to bring new products to market faster and more efficiently is
transforming clinical trial...
U.S. Orphan Product Designations More Than Doubled During Last Decade, According to Tufts Center for the Study of Drug Development
January 20, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 20, 2010) - The number of orphan product designations in the
U.S. more than doubled during the last decade, reflecting growing interest
by pharmaceutical and biotech...
Drug Companies Still Under Pressure to Increase Pace of Development, According to Tufts Center for the Study of Drug Development
January 06, 2010 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 6, 2010) - Although drug developers are improving R&D
efficiency, in part by terminating more unpromising drugs earlier in
development, their continued success...
New Products to Treat Neglected Diseases Are on the Rise, According to Tufts Center for the Study of Drug Development
November 17, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 17, 2009) - New products to treat neglected diseases have
received marketing approval from regulatory agencies at a steadily
increasing rate in recent years as...
Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
October 30, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to
replace drugs coming off patent are finding that success is increasingly
tied to the company's ability...
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
September 09, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class
drugs have fallen dramatically in recent decades -- from a median of 10.2
years in the 1970s to 2.5...